Drug sponsors gave a less than overwhelming endorsement of orphan incentives to the US Government Accountability Office, a potentially concerning revelation for advocates and other stakeholders.
The sample size was small (only four manufacturers were interviewed for the GAO study) but two of the sponsors said that orphan incentives are not a primary driver for rare disease development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?